210
Views
14
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era

, , , &
Pages 737-742 | Received 24 Jan 2015, Accepted 31 Mar 2015, Published online: 15 Jul 2015

References

  • Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
  • de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
  • Sturdee DW, Pines A, Archer DF; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302–20
  • Jalava-Broman J, Makinen J, Ojanlatva A, Jokinen K, Sillanmaki L, Rautava P. Change in the frequency of HRT use from 2000 to 2005 and reasons to discontinue: follow-up of a normal cohort in Finland. Acta Obstet Gynecol Scand 2011;90:351–7
  • Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric 2014;17: 252–9
  • Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336: 1769–75
  • Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997;277:543–7
  • Jacobs DM, Tang MX, Stern Y, et al. Cognitive function in nondemented older women who took estrogen after menopause. Neurology 1998;50:368–73
  • Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880–8
  • Regan MM, Emond SK, Attardo MJ, Parker RA, Greenspan SL. Why do older women discontinue hormone replacement therapy? J Women’s Health Gend Based Med 2001;10:343–50
  • Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000–2009. Menopause 2011;18:385–92
  • Isaacs AJ, Drew SV, McPherson K. UK women doctors’ use of hormone replacement therapy: 10-year follow up. Climacteric 2005;8:154–61
  • Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Therapeut 2009;47:617–26
  • Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012;23:223–31
  • Potocki M, Ziller R, Mueller C. Mid-regional pro-adrenomedullin in acute heart failure: a better biomarker or just another biomarker? Curr Heart Fail Rep 2012;9:244–51
  • Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int 2014;25:2721–8
  • Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies – report of the ISPOR Task Force on Retrospective Databases. Value Health 2003;6:90–7
  • Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Safety 2007;16:17–27
  • Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women’s Health Initiative Study. JAMA 2003;289:3241–2
  • Gavin NI, Thorp JM, Ohsfeldt RL. Determinants of hormone replacement therapy duration among postmenopausal women with intact uteri. Menopause 2001;8:377–83
  • Bestul MB, McCollum M, Hansen LB, Saseen JJ. Impact of the Women’s Health Initiative trial results on hormone replacement therapy. Pharmacotherapy 2004;24:495–9
  • Bretler DM, Hansen PR, Abildstrom SZ, et al. Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study. Br J Clin Pharmacol 2011;71:105–15
  • Buick DL, Crook D, Horne R. Women’s perceptions of hormone replacement therapy: risks and benefits (1980–2002). A literature review. Climacteric 2005;8:24–35
  • Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997;28:137–45
  • Oren A. Motives for initiation, temporary discontinuation, and permanent discontinuation of hormone replacement therapy use among Norwegian women. Maturitas 2009;64:33–7
  • Corrado F, D’Anna R, Caputo F, Cannata ML, Zoccali MG, Cancellieri F. Compliance with hormone replacement therapy in postmenopausal Sicilian women. Eur J Obstet Gynecol Reprod Biol 2005;118:225–8
  • Panay N, Hamoda H, Arya R, Savvas M; British Menopause Society, Women’s Health Concern. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int 2013;19:59–68

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.